tadalafil dosage - viagra - augmentin uses - http://sildenafilgeneric-citrate.com/ - levitra 20mg vs viagra 100mg - furosemide for dogs - lisinopril hctz - cialis generic - gabapentin 300mg - doxycycline hyclate 100mg

Posts Tagged 'Type 1 Diabetes'

As Diabetes Becomes Global Epidemic, PharmaCyte Biotech’s Insulin Producing Cells Receive 20 Years of Protection

As Diabetes Becomes Global Epidemic, PharmaCyte Biotech’s Insulin Producing Cells Receive 20 Years of Protection

Written by Ι Stock Market Media — July 19, 2016

Worldwide the number of people living with diabetes has reached 422 million, and if the current trend continues, over 700 million people are expected to be living with diabetes by 2025. Diabetes has clearly become a healthcare crisis on a global scale, and PharmaCyte Biotech (OTCQB: PMCB) recently received some good news in the form of patent protection that will help the company do its part in bringing a treatment to tens of ...

Read More →
0

PharmaCyte Biotech Outlines 2016 Milestones as Company Moves Into Cancer Clinical Trial

PharmaCyte Biotech Outlines 2016 Milestones as Company Moves Into Cancer Clinical Trial

SILVER SPRING, Md., Jan. 06, 2016 — PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today the Company’s 2016 milestones as it advances its new treatment for pancreatic cancer into the clinic in the United States with study sites in Europe and Australia.

PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, stated, “We are excited to see 2016 ...

Read More →
0

PharmaCyte Biotech Releases Video Highlighting Diabetes Treatment Development Program

PharmaCyte Biotech Releases Video Highlighting Diabetes Treatment Development Program

SILVER SPRING, Md., Dec. 15, 2015 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has released a new video that highlights PharmaCyte’s diabetes treatment development program. PharmaCyte invited Stock Market Media Group to sit in on its 2nd Annual International Diabetes Consortium in Vienna, Austria, to document PharmaCyte’s story related to the development of its treatment ...

Read More →
0

PharmaCyte Biotech Creates Faster Path to the Clinic For Company’s Diabetes Treatment

PharmaCyte Biotech Creates Faster Path to the Clinic For Company’s Diabetes Treatment

Written by Ι Stock Market Media — May 20, 2015

PharmaCyte Biotech (OTCQB: PMCB) has managed to do something that is rarely done in science – bring together an international group of leading experts to work on one project. The project that is drawing their interest is PharmaCyte Biotech’s diabetes treatment and getting it into the hands of insulin-dependent patients around the world. These experts have become known collectively as the “International Diabetes Consortium,” and if PharmaCyte is to be successful, it will ...

Read More →
0

Nuvilex, Inc. Expects its Technology Can Start to Change Life for Diabetics

Nuvilex, Inc. Expects its Technology Can Start to Change Life for Diabetics

Written by ι Stock Market Media — April 8, 2013

When Nuvilex, Inc. (OTCQB: NVLX) started its diabetes studies, it was likely well known then that while its late-stage pancreatic cancer trials are front and center, it is the company’s work in diabetes that could put it on the map and really turn some heads.  The small Silver Spring, Maryland, biotechnology company is already getting attention for its cell encapsulation technology’s performance in its preclinical diabetes studies, and ...

Read More →
0
ContactUs.com